|
|
english
|
español
|
français
|
Sign Up for an Account
|
Sign In
Country Profiles...
Home
The BCH
The Protocol
Finding Information
Registering Information
Resources
Help
Finding Information
National Contacts
Laws and Regulations
Country's Decisions and other Communications
Submissions
Risk Assessments
Roster of Experts
LMOs, Genes or Organisms
National Reports
Capacity-Building
Organizations
The BCH Virtual Library
Survey on indicators (2014)
Compiled Information
National Contacts
LMO Registry
Organism Registry
Gene Registry
Go to record ID
Home
|
Finding Information
|
Record details
Modified Organism
VECTORMUNE® FP-LT + AE Vaccine
LMO Information
Decisions on the LMO
Risk Assessments
Record information and status
Record ID
105176
Status
Published
Date of creation
2014-01-09 10:23 UTC (gutemberg.sousa@mctic.gov.br)
Date of last update
2014-01-27 15:03 UTC (dina.abdelhakim@cbd.int)
Date of publication
2014-01-27 15:03 UTC (dina.abdelhakim@cbd.int)
Tweeter
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the
LMO quick-links
page.
LMO name
VECTORMUNE® FP-LT + AE Vaccine
Transformation event
FP/LT
Developer(s)
Record #105170
Dr Alexis Henry Gaetan Goux
President of CIBio
Ceva Saúde Animal Ltda (CEVA)
Rua Manuel Joaquim Filho, 303 Pulínia - SP
Paulínia, São Paulo
Brazil, 13140-000
Phone:
551938337700
Fax:
55193833-7722
Email:
alexisgoux@ceva.com
Url:
CEVA
Description
VECTORMUNE FP-LT + AE is a genetically engineered, live fowlpox virus vaccine for use in chickens. The fowlpox virus has been genetically modified to express key protective laryngotracheitis (LT) virus antigens. In addition to the fowlpox virus vector, this freeze-dried vaccine contains a conventional live avian encephalomyelitis (AE) virus for use as an aid in the prevention of avian encephalomyelitis.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Record #105171
Fowlpox virus - FOWPV
Related LMOs
Record #105206
VECTORMUNE® FP-LT Vaccine
Dr Alexis Henry Gaetan Goux Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Characteristics of the transformation process
Vector
pUC18
Techniques used for the modification
Homologous Recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Record #105174
Glycoprotein B gene - Gallid herpesvirus 1 - ILTV
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Record #105173
UL32 gene - Gallid herpesvirus 1 - ILTV
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
Two genes originating from ILTV, namely UL32 and gB, were introduced into a FPV vector. The genes were ligated into a pUC18 transformation vector in addition to a lacZ marker gene from E. coli, using two synthetic promoters and an FPV homologous recombination site.
The vector was constructed by cloning a 3 kb fragment of FPV genomic DNA into the pUC18 vector. An internal fragment of 175bp was removed and replaced by a construct containing the UL32 coding sequenece with a synthetic PS promoter, followed by a lacZ gene directed by the synthetic promoter P17. This was followed by the coding sequence of the gB gene which was also directed by the synthetic promoter PS.
The synthetic promoters PS and P17 emulate the consensus early/late promoter and the early poxvirus promoter, respectively. Genes gB and UL32 code for the ILTV antigens, while the gene lacZ operates as a reporter gene to facilitate recombinant virus selection.
This construct and the the parental FPV strain were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.
Homologous recombination and integration of the genetic construct was confirmed by Southern blot using probes that hybridized in both sides of the insertion site. DNA sequencing was also conducted. Expression of genes UL32 and gB was confirmed by Western blot.
LMO characteristics
Modified traits
Production of medical or pharmaceutical compounds (human or animal)
Vaccines
Common use(s)
Vaccine
Additional Information
Other relevant website address or attached documents
Vectormune® FP-LT+AE - Biomune Company
Vectormune® FP-LT+AE - CTNBio
Records referencing this document
(
3
)
ID
Description
3
record(s) found
Country's Decision or any other Communication
1 record
Modified Organism
1 record
Risk Assessment
1 record
Contact us
|
Site Map
|
Linkages Policy
|
Privacy Policy
|
Disclaimer
|
© SCBD 2001-2016
Rate this page
- 56 people have rated this page